



Appendix 2

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Gunton JE, Cheung NW, Davis TME, et al. A new blood glucose management algorithm for type 2 diabetes. A position statement of the Australian Diabetes Society. *Med J Aust* 2014; 201: 650-653. doi: 10.5694/mja14.01187.

Table 2. Medication combinations potentially attracting PBS subsidy

Medication	Met	SU	Acar.	Pio	Rosi	DPP4i	SGLT2i	Exen.	Insulin*
Monotherapy									
	<u>YES</u>	<u>YES</u>	<u>YES</u>	NO	NO	NO	NO	NO	<u>YES</u>
Dual therapy with									
Metformin	n/a	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>
Sulfonylurea	<u>YES</u>	n/a	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>
Acarbose	<u>YES</u>	<u>YES</u>	n/a	NO	NO	NO	NO	NO	<u>YES</u>
Pioglitazone	<u>YES</u>	<u>YES</u>	NO	n/a	NO	NO	NO	NO	<u>YES</u>
Rosiglitazone	<u>YES</u>	<u>YES</u>	NO	NO	n/a	NO	NO	NO	NO
DPP4 inhibitor	<u>YES</u>	<u>YES</u>	NO	NO	NO	n/a	NO	NO	NO
SGLT2 inhibitor	<u>YES</u>	<u>YES</u>	NO	NO	NO	NO	n/a	NO	NO
Exenatide	<u>YES</u>	<u>YES</u>	NO	NO	NO	NO	NO	n/a	NO
Insulin	<u>YES</u>	<u>YES</u>	<u>YES</u>	<u>YES</u>	NO	NO	NO	NO	n/a
Triple therapy with									
M + SU	n/a	n/a	<u>YES</u>	<u>YES</u>	NO	NO	NO	<u>YES</u>	<u>YES</u>
M + Acarbose	n/a	<u>YES</u>	n/a	NO	NO	NO	NO	NO	<u>YES</u>
M + Pioglitazone	n/a	<u>YES</u>	NO	n/a	NO	NO	NO	NO	NO
M + Rosiglitazone	n/a	NO	NO	n/a	NO	NO	NO	NO	NO
M + DPP4i	n/a	NO	NO	NO	NO	n/a	NO	NO	NO
M + SGLT2i	n/a	NO	NO	NO	NO	NO	n/a	NO	NO
M + GLP-1RA	n/a	<u>YES</u>	NO	NO	NO	NO	NO	n/a	NO
M + Insulin	n/a	<u>YES</u>	<u>YES</u>	NO	NO	NO	NO	NO	n/a
SU + Acarbose	<u>YES</u>	n/a	n/a	NO	NO	NO	NO	NO	NO
SU + Pioglitazone	<u>YES</u>	n/a	NO	n/a	NO	NO	NO	NO	NO
SU + Rosiglitazone	NO	n/a	NO	n/a	NO	NO	NO	NO	NO
SU + DPP4i	NO	n/a	NO	NO	NO	n/a	NO	NO	NO
SU + SGLT2i	NO	n/a	NO	NO	NO	NO	n/a	NO	NO
SU + GLP-1RA	<u>YES</u>	n/a	NO	NO	NO	NO	NO	n/a	NO
SU + Insulin	<u>YES</u>	n/a	<u>YES</u>	NO	NO	NO	NO	NO	n/a
Ac + Pioglitazone	NO	NO	n/a	n/a	n/a	NO	NO	NO	NO
Ac + Rosiglitazone	NO	NO	n/a	n/a	n/a	NO	NO	NO	NO
Ac + DPP4i	NO	NO	n/a	NO	NO	n/a	NO	NO	NO
Ac + SGLT2i	NO	NO	n/a	NO	NO	NO	n/a	NO	NO
Ac + GLP-1RA	NO	NO	n/a	NO	NO	NO	NO	n/a	NO
Ac + Insulin	<u>YES</u>	<u>YES</u>	n/a	NO	NO	NO	NO	NO	n/a
TZD + DPP4i	NO	NO	NO	n/a	n/a	n/a	NO	NO	NO
TZD + SGLT2i	NO	NO	NO	n/a	n/a	n/a	NO	NO	NO
TZD + GLP-1RA	NO	NO	NO	n/a	n/a	NO	NO	n/a	NO
TZD + insulin	NO	NO	NO	n/a	n/a	NO	NO	NO	n/a
DPP4i + SGLT2i	NO	NO	NO	NO	NO	n/a	n/a	NO	NO
DPP4i + GLP-1RA	NO	NO	NO	NO	NO	n/a	NO	n/a	NO
DPP4i + Insulin	NO	NO	NO	NO	NO	n/a	NO	NO	n/a
SGLT2i + exenatide	NO	NO	NO	NO	NO	n/a	NO	n/a	NO
SGLT2i + Insulin	NO	NO	NO	NO	NO	NO	n/a	NO	n/a
GLP-1a + Insulin	NO	NO	NO	NO	NO	NO	NO	n/a	n/a

PBS=pharmaceutical benefits scheme. Met=metformin. SU=sulfonylurea. Acar=acarbose. Pio=pioglitazone. Rosi=rosiglitazone. DPP4i= dipeptidyl peptidase 4 inhibitor. SGLT2i = sodium glucose cotransporter 2 inhibitor. Exen = exenatide. M=metformin. Ac=acarbose. TZD=thiazolidinedione. YES=potentially PBS-subsidised, NO=not, n/a = not applicable. GLP-1RA=glucagon-like-peptide-1 receptor agonist.